晚期原发性肝癌患者慢性乙型肝炎病毒感染索拉非尼耐药的临床研究

发布时间：2018-06-28 20:43

本文选题：索拉非尼耐药 + 晚期原发性肝癌　；参考：《中华医院感染学杂志》2015年19期

【摘要】：目的探讨索拉非尼耐药的晚期原发性肝癌患者慢性乙型肝炎病毒(HBV)感染临床效果,研究其对患者的不良反应、治疗效果等。方法回顾性分析2012年6月-2014年6月医院收治的42例索拉非尼耐药晚期原发性肝癌患者临床资料,将采用FOLFOX 4方案化疗的20例患者设为对照组,将采用XELOX方案化疗的22例患者设为试验组,观察两组患者临床疗效的差异,同时评价患者甲胎蛋白(AFP)水平、不良反应,采用SPSS19.0软件对数据进行统计分析。结果试验组患者部分缓解率为18.2%,稍高于对照组的15.0%,疾病稳定率为36.4%,稍低于对照组的45.0%,两组比较差异无统计学意义;试验组患者治疗后AFP显著下降,同时其低于同期对照组,比较差异有统计学意义(P0.05);试验组患者Ⅲ度骨髓抑制率为9.1%,低于对照组的35.0%,两组比较差异有统计学意义(P0.05)。结论索拉非尼耐药的晚期原发性肝癌并发慢性HBV感染患者治疗较为棘手,XELOX方案或FOLFOX 4方案具有一定的疗效,但XELOX方案骨髓抑制少、不良反应小,进而延缓患者疾病进展、增加其治疗依从性,值得临床选择。
[Abstract]:Objective to investigate the clinical effect of chronic hepatitis B virus (HBV) infection in patients with sorafenib resistant advanced primary liver cancer (HCC), to study the adverse effects and therapeutic effects of the patients. Methods the clinical data of 42 patients with sorafenib resistant advanced primary liver cancer admitted in June June 2012, -2014 years, were retrospectively analyzed, and FOLFOX 4 would be used. 20 patients with chemotherapy were set up as control group, and 22 patients with XELOX chemotherapy were set up as experimental group. The difference of clinical efficacy between the two groups was observed, and the level of alpha fetoprotein (AFP) and adverse reactions were evaluated, and the data were statistically analyzed by SPSS19.0 software. The results of partial remission rate of the patients in the test group were 18.2%, slightly higher than that of the two groups. In group 15%, the rate of disease stability was 36.4%, slightly lower than 45% in the control group, and there was no significant difference in the two groups. The AFP in the experimental group was significantly lower than that in the control group (P0.05), and the rate of bone marrow inhibition in the experimental group was 9.1%, lower than that of the control group (35%), and the two groups were different. Statistical significance (P0.05). Conclusion sorafenib resistant advanced primary liver cancer patients with chronic HBV infection are more difficult to treat, XELOX scheme or FOLFOX 4 scheme has a certain effect, but the XELOX scheme has fewer myelosuppression and less adverse reactions, and then postpones the disease progression and increases the compliance of the treatment. It is worthy of clinical selection.
【作者单位】：苏州中西医结合医院内四科;苏州大学附属儿童医院内一科;苏州大学附属第一医院消化科;青海省人民医院消化科;
【基金】：国家重点基础研究发展规划基金资助项目(G1998051211)
【分类号】：R735.7;R512.62

【共引文献】